Table 1.
Characteristics of the Patients at Baseline.*
| Characteristic | 1-Month Group (N =1496) | 9-Month Group (N =1504) | All Patients (N = 3000) |
|---|---|---|---|
| Continent of residence — no. (%) | |||
| Africa | 772 (52) | 781 (52) | 1553 (52) |
| Asia | 121 (8) | 124 (8) | 245 (8) |
| South America | 360 (24) | 355 (24) | 715 (24) |
| North America | 243 (16) | 244 (16) | 487 (16) |
| Median age (IQR) — yr | 35 (28–43) | 35 (28–43) | 35 (28–43) |
| Sex — no. (%) | |||
| Male | 694 (46) | 692 (46) | 1386 (46) |
| Female | 802 (54) | 812 (54) | 1614 (54) |
| Race or ethnic group — no. (%)† | |||
| Black non-Hispanic | 992 (66) | 991 (66) | 1983 (66) |
| White non-Hispanic | 16 (1) | 12 (1) | 28 (1) |
| Asian or Pacific Islander | 122 (8) | 128 (9) | 250 (8) |
| Hispanic | 361 (24) | 369 (25) | 730 (24) |
| Unknown | 5 (<1) | 4 (<1) | 9 (<1) |
| Median body-mass index (IQR)‡ | 23.6 (20.9–27.1) | 23.5 (20.8–26.9) | 23.5 (20.9–27.1) |
| CD4+ count | |||
| Median (IQR) — no. of cells/mm3 | 473 (349–636) | 469 (341–634) | 470 (346–635) |
| Patients — no. (%) | |||
| >250 cells/mm3 | 1299 (87) | 1302 (87) | 2601 (87) |
| 100 to ≤250 cells/mm3 | 160 (11) | 165 (11) | 325 (11) |
| <100 cells/mm3 | 37 (2) | 37 (2) | 74 (2) |
| Receipt of antiretroviral therapy at entry — no. (%) | |||
| Efavirenz-based regimen | 650 (43) | 649 (43) | 1299 (43) |
| Nevirapine-based regimen | 97 (6) | 100 (7) | 197 (7) |
| Other | 3 (<1) | 6 (<1) | 9 (<1) |
| None | 746 (50) | 749 (50) | 1495 (50) |
| Viral load in patients receiving antiretroviral therapy —no./total no.(%) | |||
| Undetectable — <40 copies/ml | 569/750 (76) | 586/755 (78) | 1155/1505 (77) |
| Detectable — ≥40 copies/ml | 154/750 (21) | 143/755 (19) | 297/1505 (20) |
| Unavailable | 27/750 (4) | 26/755 (3) | 53/1505 (4) |
| Previous diagnosis of tuberculosis — no. (%) | 82 (5) | 89 (6) | 171 (6) |
| Tuberculin skin test — no. (%) | |||
| Positive | 311 (21) | 324 (22) | 635 (21) |
| Negative | 1033 (69) | 1021 (68) | 2054 (68) |
| Not done | 152 (10) | 159 (11) | 311 (10) |
| IGRA for tuberculosis — no. (%)§ | |||
| Positive | 36 (2) | 37 (2) | 73 (2) |
| Negative | 1 (<1) | 2 (<1) | 3 (<1) |
| Not done | 1459 (98) | 1465 (97) | 2924 (97) |
*
Patients in the 1-month group were assigned to receive a regimen of daily rifapentine plus isoniazid, and those in the 9-month group were assigned to receive daily isoniazid alone. Percentages may not total 100 because of rounding. IQR denotes interquartile range.
†
Race or ethnic group was reported by the patients.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.
§
Results of the interferon-γ release assay (IGRA) were available only for patients at sites in the United States.